BiomX Inc. (PHGE) |
|
0.3434 -0.042 (-10.92%)
|
02-07 16:00 |
|
Open: |
0.3998 |
Pre. Close: |
0.3855 |
|
High:
|
0.3929 |
Low:
|
0.31 |
|
Volume:
|
200,554 |
Market Cap:
|
10(M) |
|
|
|
Technical analysis |
as of: 2023-02-07 4:30:56 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.51 One year: 0.59 |
| Support: |
Support1: 0.27  Support2: 0.18 |
| Resistance: |
Resistance1: 0.43 Resistance2: 0.51 |
| Pivot: |
0.34 |
| Moving Average: |
MA(5): 0.37  MA(20): 0.32
MA(100): 0.3 MA(250): 0.74 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 65 %D(3): 72.2 |
| RSI: |
RSI(14): 56.1 |
| 52-week: |
High: 2.14 Low: 0.13 |
| Average Vol(K): |
3-Month: 473 (K) 10-Days: 200 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PHGE ] has closed above bottom band by 50.0%. Bollinger Bands are 16.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.4 - 0.4 |
0.4 - 0.4 |
|
Low:
|
0.31 - 0.31 |
0.31 - 0.31 |
|
Close:
|
0.34 - 0.34 |
0.34 - 0.35 |
|
Company Description |
|
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. |
Headline News |
Tue, 24 Jan 2023
Do Traders Think Biomx Inc (PHGE) Can Keep Climbing Tuesday? - InvestorsObserver
Fri, 20 Jan 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Fri, 23 Dec 2022
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday - Benzinga
Wed, 09 Nov 2022
BiomX Reports Third Quarter 2022 Financial Results and Provides ... - GlobeNewswire
Wed, 06 Jul 2022
BiomX Announces Voluntary Delisting from the Tel Aviv Stock ... - Business Wire
Tue, 28 Jun 2022
Boehringer Ingelheim and BiomX Collaborate to Discover ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
29 (M) |
| Shares Float |
17 (M) |
|
% Held by Insiders
|
20 (%) |
|
% Held by Institutions
|
24.3 (%) |
|
Shares Short
|
31 (K) |
|
Shares Short P.Month
|
111 (K) |
Stock Financials |
|
EPS
|
-1.42 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.88 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-27.7 |
|
Return on Equity (ttm)
|
-58.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.19 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-26 (M) |
|
Levered Free Cash Flow
|
-17 (M) |
Stock Valuations |
|
PE Ratio
|
-0.25 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.18 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.39 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
